A Retrospective Analysis Comparing Orca-T to Post-transplant Cyclophosphamide Based Allogeneic Hematopoietic Stem Cell Transplant in Patients With Matched Unrelated Donors Receiving Myeloablative Conditioning
Phase I Trial Results for Patients With Advanced Hematological Malignancies Treated With Orca-T Cell Therapy With Reduced Intensity Conditioning and Single Agent Tacrolimus